Latest News:
FDA Approves Oxbryta™ (Voxelotor), the First Medicine Specifically Targeting the Root Cause of Sickle Cell Disease
TIF will coordinate efforts for patients’ information on Reblozyl in 62 countries
New and Updated Data on Key Thalassaemia & SCD Pipeline Therapies at the American Society of Hematology (ASH) 2019 Annual Meeting – 7-10 December 2019
Deferasirox Mylan: A new generic drug for the treatment of iron overload in β-thalassaemia major obtained approval by the EMA
US government & Gates Foundation pledge $200 million to bring gene therapies to patients with Sickle Cell Disease & HIV
ar
de
el
en
fr
it
TIF
A PROPOSITO DI…
FORMAZIONE
ATTIVITÀ IN LOCO
POSIZIONI E POLITICHE
PROGETTI
PUBBLICAZIONI
NOVITÀ ED EVENTI
CONTATTI
Home
»
NOVITÀ ED EVENTI
NOVITÀ ED EVENTI
Subscribe
2018-07-24
tifwp
Cookies
This site uses cookies.
Find out more
Okay, thanks